MINNEAPOLIS | January 6, 2026 — CVRx, Inc. has announced the implementation of new Category I Current Procedural Terminology (CPT) codes for Barostim™ Therapy, effective January 1, 2026. The transition from Category III to Category I CPT codes marks formal recognition of Barostim as an established medical procedure, supporting nationwide adoption, consistent reimbursement, and standardized clinical use for patients with cardiovascular disease, particularly heart failure.
Science Significance
From a scientific and clinical innovation standpoint, the new CPT coding milestone reinforces the maturation of baroreflex activation therapy as a validated neuromodulation approach. Barostim is an implantable device delivering electrical pulses to carotid artery baroreceptors, designed to restore autonomic nervous system balance in patients with heart failure. Recognition through Category I CPT codes reflects accumulated clinical evidence demonstrating reproducible outcomes and established procedural standards, distinguishing Barostim from emerging or investigational technologies. This milestone signals that neuromodulation has progressed from novel concept to integrated cardiovascular therapy, expanding the scientific acceptance of device-based autonomic modulation.
Regulatory Significance
From a regulatory and compliance perspective, Category I CPT codes represent a critical post-approval lifecycle milestone. Unlike temporary Category III codes, Category I codes require evidence of widespread clinical use, proven safety and effectiveness, and acceptance within the medical community. Their implementation confirms that Barostim has met stringent criteria aligned with regulatory expectations, clinical guidelines, and quality frameworks. For cGxP stakeholders, this underscores the importance of robust clinical data generation, post-market surveillance, and procedural standardization in sustaining long-term regulatory success for implantable medical devices.
Business Significance
Advertisement
Commercially, the transition to Category I CPT codes is a material catalyst for predictable reimbursement and scalable growth. Standardized coding enables hospitals and physicians to streamline billing processes, reduce reimbursement uncertainty, and confidently expand procedural volume. For CVRx, this development strengthens Barostim’s position within the heart failure treatment continuum, supporting broader adoption across U.S. healthcare systems. Reliable reimbursement is a key determinant of market penetration in MedTech, and this milestone enhances CVRx’s ability to plan manufacturing, sales expansion, and long-term commercialization strategy with greater confidence.
Patients’ Significance
For patients living with heart failure, the implementation of Category I CPT codes translates into improved access to an FDA-approved therapy with demonstrated clinical benefit. Reimbursement clarity reduces barriers to care, making it more likely that eligible patients can receive Barostim therapy without delays related to coverage uncertainty. Consistent national coding supports equitable access across healthcare settings, helping ensure that innovative therapies reach patients who may have limited options with pharmacologic treatment alone. Ultimately, this milestone may contribute to improved symptom control, quality of life, and continuity of care for a high-risk patient population.
Policy Significance
At a health policy level, the establishment of Category I CPT codes reflects broader system priorities around evidence-based adoption of advanced medical technologies. CPT classification influences coverage decisions, care pathway integration, and long-term healthcare spending models. Recognition of Barostim therapy signals policy alignment with device-based solutions that address chronic cardiovascular disease burden, particularly where traditional therapies may be insufficient. Such milestones support a policy environment that rewards validated innovation while maintaining procedural standardization and accountability.
Overall, the implementation of Category I CPT codes for Barostim Therapy represents a defining moment in the therapy’s clinical and commercial lifecycle. For the cGxP.wire audience, this announcement highlights how scientific validation, regulatory rigor, and reimbursement alignment converge to enable sustainable MedTech innovation. As CVRx continues to advance neuromodulation solutions for cardiovascular disease, this milestone positions Barostim as a fully integrated, reimbursable therapy within modern heart failure care.
Source: CVRx, Inc press release
